Get notified of page updates

Categories Side Effects

FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you. XRAY is a reliable source of hereditary cancer research-related news and information.
How To Use XRAY ›
Showing 11 through 20 out of 40

Relevance: Medium-High

Strength of Science: High

Research Timeline: Post Approval

29 November 2022

Guideline : Guidelines on exercise, diet, and weight during cancer treatment

Most relevant for: People currently undergoing treatment for cancer

Most professional guidelines on exercise, diet and weight management have focused on the health of the general population and cancer survivors. The American Society of Clinical Oncology (ASCO) has now published evidence-based recommendations for exercise, diet and weight specifically for people who are in active treatment for cancer. (Posted 11/29/22)  Este artículo está disponible en español.

READ MORE  ›

Relevance: Medium-High

Strength of Science: Medium

Research Timeline: Post Approval

9 November 2022

Study : More is not better: PARP dose can be safely reduced for people with ovarian cancer

Most relevant for: People taking a PARP inhibitor for ovarian cancer maintenance therapy

Maintenance therapy with a PARP inhibitor is now the standard of care for many people with advanced or recurrent ovarian cancer. However, PARP inhibitors may have significant side effects. This study shows that reducing the dose of a PARP inhibitor does not affect survival. (Posted 11/8/22)

Este artículo está disponible en español.

READ MORE  ›

Relevance: High

Research Timeline: Post Approval

2 November 2022

Update : Strategies for managing pancreatic cancer pain

Most relevant for: People with pancreatic cancer who are dealing with related pain.

Abdominal pain is often a severe, ongoing symptom of pancreatic cancer, yet little research has been done on how to best reduce this pain. The authors of this review discuss current strategies for managing cancer-related pain and their effectiveness. (Posted 10/31/22)

Este artículo está disponible en español.

READ MORE  ›

Relevance: High

Strength of Science: Medium-High

Research Timeline: Post Approval

29 September 2022

Study : Acupuncture may ease breast cancer treatment side effects

Most relevant for: People considering acupuncture for managing breast cancer treatment symptoms.

Acupuncture can ease some symptoms of breast cancer treatment. Multiple studies found that acupuncture is a safe and effective strategy to manage certain symptoms but also called for more rigorous research on the topic. (Posted 9/28/22) Este artículo está disponible en español.

READ MORE  ›

Relevance: Medium

Research Timeline: Post Approval

27 September 2022

Update : FDA reports on new cancers linked to breast implants

Most relevant for: People with breast implants

New cancers have been found in women with both textured and smooth implants that are filled with either saline or silicone. These cancers are extremely rare. The FDA has reported cases of a type of skin cancer and blood cancers in the scar tissue that forms around breast implants. The newly reported lymphomas are different from the previously reported breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). (Posted 9/27/22). Este artículo está disponible en español.

READ MORE  ›

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Human Research

6 September 2022

Study : PARP inhibitor treatment for metastatic prostate cancer shows most benefit in men with inherited BRCA mutations

Most relevant for: People with metastatic castration resistant prostate cancer who have an inherited or tumor mutation in BRCA2.

This study looked at the benefit of using the PARP inhibitor niraparib to treat metastatic castration-resistant prostate cancer (mCRPC). Participants included those with an inherited or tumor mutation in BRCA1 or BRCA2 or an inherited or tumor mutation in another gene that affects DNA repair. Participants with an inherited or tumor mutation in BRCA1 or BRCA2 had better survival compared to those without a BRCA mutation. Side effects from niraparib were common, and consistent with previous reports for PARP inhibitors.  (posted 9/6/2022)

Este artículo está disponible en español.

READ MORE  ›

Relevance: Medium-High

Strength of Science: High

Research Timeline: Post Approval

2 August 2022

Study : Physical activity may decrease fatigue associated with cancer treatment

Most relevant for: Cancer patients who are experiencing fatigue related to cancer or its treatment.

Many cancer survivors experience fatigue during and after they complete treatment. This study looked at the effect of home-based physical activity on fatigue in cancer survivors. It also looked at whether frequent counseling encouraged people to start and continue their exercise routines.  (Posted 8/1/22). Este artículo está disponible en español.

READ MORE  ›

Relevance: High

Strength of Science: Medium-High

Research Timeline: Post Approval

29 June 2022

Study : The hidden financial burden of treating cancer care symptoms

Most relevant for: People who are experiencing side effects due to cancer treatment or cancer.

Drugs commonly used to treat symptoms of cancer and cancer treatment side effects can cost thousands of dollars out of pocket for patients, depending on what drugs are used. (Posted 6/29/2022). Este artículo está disponible en español.

READ MORE  ›

Relevance: Medium

Strength of Science: Medium-High

Research Timeline: Post Approval

14 April 2022

Study : Increasing melatonin use raises concerns

Most relevant for: people who take or consider taking melatonin to help with sleep.

Adult use of melatonin as a sleep aid has increased even though its benefits and risks are not well understood. This study looked at trends in melatonin use over the last 19 years. (Posted 4/14/2022)

Este artículo está disponible en español.

READ MORE  ›

Relevance: Medium-High

Strength of Science: High

Research Timeline: Post Approval

22 February 2022

Study : Quality of life for people with early-stage breast cancer who participated in the OlympiA clinical trial

Most relevant for: People with inherited mutations in BRCA1 or BRCA2 who have been diagnosed with early-stage, HER2-negative breast cancer.

The OlympiA study showed that the PARP inhibitor olaparib (Lynparza) is effective when used as maintenance therapy for people with an inherited BRCA1 or BRCA2 mutation who have early-stage breast cancer. Patient-reported outcomes from OlympiA suggest that olaparib was well tolerated and did not reduce quality of life or delay recovery from chemotherapy. (posted 2/22/22) Update: Based on OlympiA results, the FDA approved olaparib as adjuvant treatment for people with an inherited BRCA mutation who were diagnosed with early-stage HER2-negative breast cancer at high risk for recurrence. (03/11/2022). 

Este artículo está disponible en español.

READ MORE  ›